Cargando…

[(111)In]PSMA-I&T: expanding the spectrum of PSMA-I&T applications towards SPECT and radioguided surgery

BACKGROUND: The relevance of prostate-specific membrane antigen (PSMA) targeting in the clinical management of prostate cancer (PCa) is continually increasing, entailing the development of PSMA-targeted molecular probes. Recently, a first PSMA-targeted theranostic concept has been successfully imple...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schottelius, Margret, Wirtz, Martina, Eiber, Matthias, Maurer, Tobias, Wester, Hans-Jürgen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2015
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4659791/ https://www.ncbi.nlm.nih.gov/pubmed/26608882 http://dx.doi.org/10.1186/s13550-015-0147-6

Ejemplares similares

Effect of Carbohydration on the Theranostic Tracer PSMA I&T
por: Schmidt, Alexander, et al.
Publicado: (2018)

[(99cm)Tc]Tc-PSMA-I&S-SPECT/CT: experience in prostate cancer imaging in an outpatient center
por: Werner, P., et al.
Publicado: (2020)

EAU Biochemical Recurrence Risk Classification and PSA Kinetics Have No Value for Patient Selection in PSMA-Radioguided Surgery (PSMA-RGS) for Oligorecurrent Prostate Cancer
por: Falkenbach, Fabian, et al.
Publicado: (2023)

A CT-based radiomics model to detect prostate cancer lymph node metastases in PSMA radioguided surgery patients
por: Peeken, Jan C., et al.
Publicado: (2020)

Synthesis and in vitro and in vivo evaluation of urea-based PSMA inhibitors with increased lipophilicity
por: Wirtz, Martina, et al.
Publicado: (2018)

Heterogeneity of prostate-specific membrane antigen (PSMA) and PSMA-ligand uptake detection combining autoradiography and postoperative pathology in primary prostate cancer
por: Wang, Hui, et al.
Publicado: (2023)

Synthesis and preclinical evaluation of novel (18)F-labeled Glu-urea-Glu-based PSMA inhibitors for prostate cancer imaging: a comparison with (18)F-DCFPyl and (18)F-PSMA-1007
por: Robu, Stephanie, et al.
Publicado: (2018)

Synthesis and Preclinical Characterization of the PSMA-Targeted Hybrid Tracer PSMA-I&F for Nuclear and Fluorescence Imaging of Prostate Cancer
por: Schottelius, Margret, et al.
Publicado: (2019)

Synthesis and preclinical evaluation of DOTAGA-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer
por: Weineisen, Martina, et al.
Publicado: (2014)

Synthesis and preclinical evaluation of novel (99m)Tc-labeled PSMA ligands for radioguided surgery of prostate cancer
por: Kunert, Jan-Philip, et al.
Publicado: (2023)

PSMA-targeted imaging of prostate cancer: evolution of a success story
por: Maurer, Tobias, et al.
Publicado: (2017)

Radiochemical and biological assessments of a PSMA-I&S cold kit for fast and inexpensive (99m)Tc-labeling for SPECT imaging and radioguided surgery in prostate cancer
por: Fuscaldi, Leonardo Lima, et al.
Publicado: (2023)

Automated synthesis and quality control of [(99m)Tc]Tc-PSMA for radioguided surgery (in a [(68)Ga]Ga-PSMA workflow)
por: Aalbersberg, Else A., et al.
Publicado: (2020)

Biodistribution and dosimetry for combined [(177)Lu]Lu-PSMA-I&T/[(225)Ac]Ac-PSMA-I&T therapy using multi-isotope quantitative SPECT imaging
por: Delker, Astrid, et al.
Publicado: (2023)

Safety and efficiency of repeat salvage lymph node dissection for recurrence of prostate cancer using PSMA-radioguided surgery (RGS) after prior salvage lymph node dissection with or without initial RGS support
por: Falkenbach, Fabian, et al.
Publicado: (2023)

Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate Cancer
por: Staniszewska, Magdalena, et al.
Publicado: (2021)

Application of machine learning to pretherapeutically estimate dosimetry in men with advanced prostate cancer treated with (177)Lu-PSMA I&T therapy
por: Xue, Song, et al.
Publicado: (2022)

Image-based dosimetry for (225)Ac-PSMA-I&T therapy using quantitative SPECT
por: Gosewisch, A., et al.
Publicado: (2020)

Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent
por: Chatalic, Kristell L.S., et al.
Publicado: (2016)

Preclinical biodistribution and dosimetry and human biodistribution comparing (18)F-rhPSMA-7 and single isomer (18)F-rhPSMA-7.3
por: Knorr, Karina, et al.
Publicado: (2022)

PSMA-PET for Lymph Node Detection in Recurrent Prostate Cancer: How do we use the Magic Bullet?
por: Maurer, Tobias, et al.
Publicado: (2017)

Validation of [(125)I]CPCR4.3 as an investigative tool for the sensitive and specific detection of hCXCR4 and mCXCR4 expression in vitro and in vivo
por: Schottelius, Margret, et al.
Publicado: (2019)

Comparison of the radiolabeled PSMA-inhibitor (111)In-PSMA-617 and the radiolabeled GRP-R antagonist (111)In-RM2 in primary prostate cancer samples
por: Schollhammer, Romain, et al.
Publicado: (2019)

Design of PSMA ligands with modifications at the inhibitor part: an approach to reduce the salivary gland uptake of radiolabeled PSMA inhibitors?
por: Felber, Veronika Barbara, et al.
Publicado: (2021)

Pitfalls in PSMA imaging: [(18)F]rhPSMA-7-PET/CT reveals presence of chrondrosarcoma
por: Feuerecker, B., et al.
Publicado: (2021)

(68)Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report
por: Rauscher, Isabel, et al.
Publicado: (2016)

Radiohybrid Ligands: A Novel Tracer Concept Exemplified by (18)F- or (68)Ga-Labeled rhPSMA Inhibitors
por: Wurzer, Alexander, et al.
Publicado: (2020)

E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET
por: Ceci, Francesco, et al.
Publicado: (2021)

2021: the year [(177)Lu]Lu-PSMA-617 RLT PSMA is ready for incorporation into clinical guidelines?: Reply to “A perspective on the EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands” by Dr. Germo Gericke
por: Herrmann, Ken, et al.
Publicado: (2021)

The effect of ligand amount, affinity and internalization on PSMA-targeted imaging and therapy: A simulation study using a PBPK model
por: Begum, Nusrat J., et al.
Publicado: (2019)

PSMA-ligand uptake can serve as a novel biomarker in primary prostate cancer to predict outcome after radical prostatectomy
por: Wang, Hui, et al.
Publicado: (2021)

Influence of sampling schedules on [(177)Lu]Lu-PSMA dosimetry
por: Rinscheid, Andreas, et al.
Publicado: (2020)

Integration of (68)Ga-PSMA-PET imaging in planning of primary definitive radiotherapy in prostate cancer: a retrospective study
por: Dewes, Sabrina, et al.
Publicado: (2016)

Direct comparison of (99m)Tc-PSMA SPECT/CT and (68)Ga-PSMA PET/CT in patients with prostate cancer
por: Albalooshi, Batool, et al.
Publicado: (2020)

Expanding the role of PSMA PET in active surveillance
por: Jain, Anika, et al.
Publicado: (2023)

Results from extended lymphadenectomies with [(111)In]PSMA-617 for intraoperative detection of PSMA-PET/CT-positive nodal metastatic prostate cancer
por: Jilg, Cordula A., et al.
Publicado: (2020)

Robot-assisted laparoscopic surgery using DROP-IN radioguidance: first-in-human translation
por: Meershoek, Philippa, et al.
Publicado: (2018)

Total Tumor Volume on (18)F-PSMA-1007 PET as Additional Imaging Biomarker in mCRPC Patients Undergoing PSMA-Targeted Alpha Therapy with (225)Ac-PSMA-I&T
por: Unterrainer, Lena M., et al.
Publicado: (2022)

(44)Sc-PSMA-617 for radiotheragnostics in tandem with (177)Lu-PSMA-617—preclinical investigations in comparison with (68)Ga-PSMA-11 and (68)Ga-PSMA-617
por: Umbricht, Christoph A., et al.
Publicado: (2017)

Response to (225)Ac-PSMA-I&T after failure of long-term (177)Lu-PSMA RLT in mCRPC
por: Ilhan, Harun, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_hhfk3kki49ohlijha6sh9l9hju